Benign Prostatic Hyperplasia

AN ENLARGED PROSTATE – known as benign prostatic hyperplasia or BPH – is caused by an overgrowth of prostate cells. This enlargement constricts the...

Erectile Dysfunction – Is Three a Crowd?

ince its launch in March 1998 Viagra has revolutionised the erectile dysfunction (ED) market. A blockbuster drug since its inception, the blue diamond-shaped pill...

French Connection

AFTER SEVERAL WEEKS of merger speculation, Sanofi-Synthelabo launched a hostile bid for French neighbours Aventis on 26th January 2004. The stock and cash deal...

THE RESOLUTION OF CONFLICT BY MUTUAL COMPROMISE

  The 10 Rules of Negotiation by Alan McCarthy Associate Consultant, Catalyst In today’s increasingly competitive sales environment, an...

Surviving in the Jungle

By Clare Willis, Senior Training Consultant, Speak First THE ABILITY TO DEVELOP GOOD WORKING relationships with a wide variety of people is a key...

The Matrix

This double special edition of the MATRIX provides a simple checklist of facts about the new GP contract. Given that this is time for...

Cancer Vaccines

THE TREATMENT OPTIONS that are available for treating cancer are surgery, radiation therapy, chemotherapy, immunotherapy, hormonal therapy, laser treatment, and biological therapies. Of all...

Blood Pressure

Blood pressure measures the force that the blood applies to the walls of the arteries as it flows through them. It’s normal for blood...

Surprised Managers

P A R T   T W O Establishing the Environment Let us take presentation skills as an...

You’re Only As Good As Your Next Sale

"I made the sale!" That's the victory cry of all salespeople. They scream, they jump up and down,...

Latest articles

Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
Praluent gets European Commission approval in certain cardiovascular patients.

EC approves Praluent®to reduce risk in ASCVD patients

The European Commission (EC) has approved a new indication for Praluent® (alirocumab), to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease...
Women meeting at a table: Pharma and women's health

Pharma and women’s health partnerships

The Primary Care Women’s Health Forum presents many opportunities for partnerships that improve women’s health. The Primary Care Women’s Health Forum (PCWHF) was originally created...

Popular articles

Pf Awards 2019 logo

Pharma talent on show at Pf Awards 2019

The biggest names in the pharmaceutical industry came together at the Royal Lancaster London on the evening of 14 March. The largest pharmaceutical sales...
Smart phone image: Digital partnerships in pharma

Digital partnerships in pharma and the NHS

Can pharma and the NHS equal the fast pace of change necessary to fully embrace technological innovation? Over the last few years, slowly but surely,...
Bristol-Myers Squibb-Pfizer Alliance announces results from Phase 4 AUGUSTUS trial.

AUGUSTUS trial demonstrates favourable safety results

The Bristol-Myers Squibb-Pfizer Alliance has announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients...
pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...

Market Access in practice: do you have a strategy?

This article is a little old... but if you're interested in Market Access we have plenty of new content: July 2018 Market Access Special Edition...